
    
      This study was a randomized, open-label, prospective clinical study in which patients were
      randomized to receive amisulpride and olanzapine for 8 weeks. Drug efficacy and safety
      assessments were assessed at baseline, 2 weekends, 4 weekends, and 8 weekends.
    
  